Study Published In The Lancet Shows Eisai's Halaven(TM)(Eribulin) Significantly Improves Overall Survival Compared With Current Treatments In Heavily Pre-Treated Metastatic Breast Cancer
HATFIELD, England, March 3, 2011 /PRNewswire/ -- New data supporting the role of Eisai's Halaven(TM) (eribulin) as a potential new standard of care for women with heavily pretreated metastatic breast…